Inhibikase Therapeutics (IKT) Interest Coverage Ratio (2020 - 2022)

Inhibikase Therapeutics (IKT) has 3 years of Interest Coverage Ratio data on file, last reported at 928119.2 in Q1 2022.

• Interest Coverage Ratio for Q1 2022 came in at 928119.2, down 416962.55% year-over-year; the trailing twelve-month figure through Dec 2022 was 3625721.6 (down 489095.22% YoY), and the FY2021 annual result was 741.16, down 673.17% from the prior year.
• Interest Coverage Ratio retreated to 928119.2 in Q1 2022 per IKT's latest filing, from 31907.98 in the prior quarter.
• Over five years, Interest Coverage Ratio peaked at 52.08 in Q2 2020 and troughed at 928119.2 in Q1 2022.
• A 3-year average of 109939.28 and a median of 222.54 in 2021 frame the typical range for Interest Coverage Ratio.
• The sharpest annual moves came in 2021 and 2022: Interest Coverage Ratio slumped 205.98% in 2021, then tumbled 416962.55% in 2022.
• A 3-year view of Interest Coverage Ratio shows it stood at 168.21 in 2020, then tumbled by 18869.2% to 31907.98 in 2021, then sank by 2808.74% to 928119.2 in 2022.
• Business Quant data shows IKT's Interest Coverage Ratio at 928119.2 in Q1 2022, 31907.98 in Q4 2021, and 28477.96 in Q3 2021.